Trial Profile
Pediatric Trials Network Long-term Antipsychotic Pediatric Safety Trial (LAPS) NICHD-2016-LAP01 Phase 4 Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary) ; Risperidone (Primary)
- Indications Autistic disorder; Bipolar disorders; Schizophrenia
- Focus Adverse reactions
- Acronyms LAPS
- 12 Feb 2024 Status changed from active, no longer recruiting to completed.
- 31 Aug 2023 Planned End Date changed from 1 Sep 2024 to 10 Jan 2024.
- 31 Aug 2023 Planned primary completion date changed from 1 Sep 2024 to 10 Jan 2024.